Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.
Viral vectors based on influenza virus, rabies virus (RV), and vaccinia virus (VV) were used to express large polypeptide segments derived from the Bacillus anthracis protective antigen (PA). For the infectious influenza virus vector and recombinant VV constructs, the receptor binding domain (RBD or domain 4) or the lethal and edema factor binding domain (LEF or domain 1') were engineered into functional chimeric hemagglutinin (HA) glycoproteins. In the case of the RV vector, the viral glycoprotein (G) was used as a carrier for RBD in an inactivated form of the vector. These constructs were examined by using multiple homologous and heterologous prime/boost immunization regimens in order to optimize the induction of alpha-PA antibody responses. Several immunization combinations were shown to induce high titers of antibody recognizing the anthrax RBD and LEF domains, as well as the full-length PA protein in mice. The heterologous prime/boost immunization regimens that involved an initial intranasal administration of a live influenza virus vector, followed by an intramuscular boost with either the killed RV vector or the VV vector, were particularly effective, inducing antigen-specific antibodies at levels severalfold higher than homologous or alternative heterologous protocols. Furthermore, sera from several groups of the immunized mice demonstrated neutralization activity in an in vitro anthrax toxin neutralization assay. In some cases, such toxin-neutralizing activity was notably high, indicating that the mechanisms by which immunity is primed by live influenza virus vectors may have beneficial properties.
Langley
William A
WA
Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, Atlanta, Georgia 30322, USA.
Bradley
Konrad C
KC
Li
Zhu-Nan
ZN
Smith
Mary Ellen
ME
Schnell
Matthias J
MJ
Steinhauer
David A
DA
D000818:Animals; D022122:Anthrax Vaccines / Q000235:genetics / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000942:Antigens, Bacterial / Q000276:immunology*; D000992:Antitoxins / Q000276:immunology*; D001427:Bacterial Toxins / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D007117:Immunization, Secondary / Q000379:methods; D051379:Mice; D008807:Mice, Inbred BALB C; D009975:Orthomyxoviridae / Q000235:genetics*; D011820:Rabies virus / Q000235:genetics; D014611:Vaccination / Q000379:methods; D014616:Vaccinia virus / Q000235:genetics
D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial; D057134:Antibodies, Neutralizing; D000942:Antigens, Bacterial; D000992:Antitoxins; D001427:Bacterial Toxins; C030325:anthrax toxin